BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
Anita ShahT CoyleS LalezariKathelijn FischerB KohlstaeddeH DelesenS RadkeL A MichaelsPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2018)
BAY 94-9027 shows an extended half-life and increased AUC vs standard-acting FVIII products. These PK characteristics will result in higher FVIII levels for longer duration.
Keyphrases